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Abstract
Background: Serum follicle stimulating hormone (FSH) levels are used clinically to evaluate infertility, pituitary and
gonadal disorders. With increased frequency of research collaborations across institutions, it is essential that inter-
laboratory validation is addressed.
Methods: An inter-laboratory validation of three commercial FSH immunoassays was performed with human
serum samples of varying frozen storage length (2 batches of 15 samples each) at -25 degree C. Percentage
differences and Bland-Altman limits of agreement were calculated.
Results: The inter- and intra-laboratory consistency of FSH values with the same assay manufacturer was much
higher after shorter-term storage (frozen for less than 11 months, mean percentage degradation less than 4%) than
after long-term storage (2-3 years, mean percentage degradation = 23%). Comparing assay results from different
manufacturers, there was similar overall long term degradation as seen with the same manufacturer (-25%),
however the degradation was greater when the original FSH was greater than 20 mIU/mL relative to less than 10
mIU/mL (p < 0.001 trend test).
Conclusion: The findings suggest that degradation of serum samples stored between 11 months and 2-3 years at
-25 degrees C can lead to unstable FSH measurements. Inter-laboratory variability due to frozen storage time and
manufacturer differences in assay results should be accounted for when designing and implementing research or
clinical quality control activities involving serum FSH at multiple study sites.
Background
Follicle-stimulating hormone (FSH) is a glycoprotein
dimer secreted by the adenohypophysis that stimulates
gametogenesis. Because serum FSH levels provide
insight into the functional capacity of the hypothalamus,
pituitary, and ovary or testis, they are frequently used
for clinical evaluation of infertility, and disorders of the
hypothalamic-pituitary-gonadal axis [1]. Specifically,
FSH levels can be used to evaluate the etiology of low
sperm counts, amenorrhea, menstrual irregularities,
pituitary disorders, precocious or delayed puberty, and
ovarian/testicular dysfunction [2,3].
Clinical determination of FSH concentration is typi-
cally measured in the serum, while measurement of
urine FSH levels has replaced those in serum for some
research protocols to avoid venipuncture. The correla-
tion between urine and serum FSH values ranges from
70% - 90% [4].
Stability of stored FSH samples has been evaluated
primarily in urine, with optimal storage conditions for
sustained FSH immunoreactivity determined to be 1-4
weeks at 4°C due to significant degradation after 4
weeks [5]. Stability of immunoreactive urinary FSH
seems most sensitive to time, with substantive declines
(about 40%) after 50 weeks at -20°C [6] and 64 weeks at
either 4°C and -20°C [7]. Storage of urine FSH samples
at either room temperature or -20°C for only 1 week
resulted in only a slight (2.8%) diminution of immunor-
eactivity [5]. Longer storage times (at least 1 year) can
be successfully used if glycerol is added to the urine
sample or the sample is extracted with acetone [7].
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poral stability of immunoreactive FSH in frozen samples.
Interestingly, a report examining the variability of serum
FSH measurements between six different immunoassays
concluded that the serum values were significantly dif-
ferent between different immunoassays. These authors
speculated that the variability might be due to differen-
tial recognition of distinct FSH isoforms by each immu-
noassay [8]. However, that report was limited by the fact
that their samples were stored at -70°C for an indeter-
minate amount of time, and the length of storage time
was not addressed in their analysis.
While inter-laboratory validity of gonadotropins has
not been well studied, inter-laboratory validity has been
well-characterized for many other hormones, particu-
larly sex steroids. For example, McShane, et al. demon-
strated that the inter-laboratory coefficient of variation
in the measurement of androstenedione, dehydroepian-
drosterone sulfate, estrone, and estrone sulfate were all
greater than 15%, resulting in large absolute differences
in measured steroid concentrations [9].
Precise and accurate measurements of serum FSH
levels are important for clinical and research purposes.
The reduction of inter-laboratory variability becomes
even more critical in collaborative, multi-center research
projects [10]. Therefore, it is important to have meticu-
lously standardized procedures for obtaining data mea-
surements to ensure that the data collection is valid
among different labs involved in a joint research
endeavor.
Currently, there are no published studies using current
assays that examine FSH stability in frozen storage. In
addition, validation of inter-laboratory measurements of
serum FSH has not been studied extensively, though
studies tend to use FSH values obtained in various
laboratories within an institution as interchangeable. In
this study, we evaluated FSH measurements of the same
sample in different labs after various lengths of storage
time. The aims of this study were to determine how fro-
zen storage time affects the validity of the FSH serum
samples and to assess inter-laboratory variability.
Methods
Hormone measurements
Validation assays were performed in three separate
laboratories: Stanford Reproductive Endocrinology and
Infertility Lab (Laboratory A), University of Virginia
Main Clinical Lab (Laboratory B), and University of
Virginia General Clinical Research Center Core Lab
(Laboratory C).
Subjects
All serum samples were from female patients of repro-
ductive age who presented to the Fertility and
Reproductive Medicine Center at Stanford University.
Patients signed an IRB-approved consent form, which
allowed storage of their serum for research purposes.
IRB approval was obtained and patient confidentiality
was protected in this study. Chronologically, this study
commenced with 15 human female serum FSH samples
that were originally drawn during 2006-2008, all during
the early follicular menstrual phase (i.e., generally cycle
days 2-5). This series of samples is subsequently termed
the “Long Term Batch”.
For the second part of the study (“Short Term Batch”),
s e r u mF S Hs a m p l e sw e r eo b t a i n e df r o mad i f f e r e n t
group of 15 women, all in the follicular phase and all in
2009.
Specimen handling
For the Long Term Batch, 15 stored samples were cho-
sen in order to represent a range of FSH values and
initially run in Lab A. Blood samples were obtained by
venipuncture, and serum was separated from the cells
by centrifugation in Lab A. On the same day as the
blood draw, the samples were analyzed and then frozen
in Lab A. The samples were de-identified and assigned a
number. These samples were stored at -25°C for a mean
of 2.3 years. Six samples were stored for three years,
eight samples were stored for two years, and one sample
was stored for 1 year. None of the lab freezers used in
this study were “frost-free” and the storage temperature
was stable.
The samples from the Long Term Batch were sent to
Labs B and C with sequential coding (sample numbers
1-15) without any information on the original assay
results. The samples were taken out of the freezer at
Lab A after their respective lengths of frozen time and
shipped overnight to Lab B on dry ice. Upon arrival at
Lab B, the samples were immediately thawed and the
immunoassays were run the same day. These samples
were then driven over to Lab C on the same day, and
the samples were analyzed at Lab C without undergoing
another freeze-thaw cycle. Each sample was only run a
single time at each lab.
For the Short Term Batch, the second 15 stored sam-
ples were again initially obtained as described above,
and run in Lab A. These samples were analyzed and fro-
zen at -25°C on the same day that the samples were
obtained. The samples remained frozen for 1-2 months
(mean = 45.27 days, range = 30-69 days) and then they
were thawed and re-assayed at Lab A. These Short
Term Batch samples were sent to Labs B and C with
sequential coding (sample numbers 16-30) without any
information on the original assay results. The samples
were shipped overnight with cold packs to Lab B on the
same day as the second Lab A assay in order to avoid
an additional freeze/thaw cycle. The next morning,
Scriver et al. Reproductive Biology and Endocrinology 2010, 8:145
http://www.rbej.com/content/8/1/145
Page 2 of 7upon arrival at Lab B, the immunoassays were run.
Again, these samples were driven to Lab C on the same
day, and the samples were analyzed at Lab C later that
day without undergoing another freeze-thaw cycle.
Therefore, these samples were all originally processed in
Lab A, and then re-run in all three Labs after 1-2
months of frozen storage at -25°C. All of these samples
were only run a single time in each lab and all measure-
ments were recorded.
The samples from the Short Term Batch were subse-
quently stored at Lab C for the next nine months at
-20°C in order to obtain FSH measurements after an
intermediate frozen storage time. After nine months, the
samples were thawed under refrigeration until comple-
tely liquid, and then assayed immediately in Lab C.
They were then refrigerated until transport, driven to
Lab B in a cooler with frozen ice packs, and then
assayed in Lab B on the same day.
Assay characteristics
At Lab A, the samples were run on an Immulite 2500
Automated Immunoassay Analyzer. This is a solid-
phase, two site chemiluminescent immunometric assay.
200 beads, coated with monoclonal murine anti-FSH are
used. The analysis is based on an alkaline phosphatase
label and a chemiluminescent substrate that uses a cen-
trifugal wash method. Three controls were run with
each assay and 2 out of 3 of the controls must be within
2 standard deviations for the run to be accepted. The
coefficient of variation (CV) for each control level was
as follows: I (mean ≅ 5) = 3.73, II (mean ≅ 15) = 4.6,
and III (mean ≅ 35) = 3.76.
At Lab B, the samples were run on a fully automated
Abbott Architect ci8200. The Architect FSH assay uses
a two-step chemiluminescent immunoassay technology
that incorporates an acridinium derivative tracer. The
CV for each control level was: I = 2.49, II = 2.65, and
III = 2.54.
At Lab C, the samples were run on an Immulite 2000
Automated Immunoassay Analyzer, which is a fully
automated, continuous random access instrument. The
Immulite 2000 has 24 reagent positions, and uses the
same reagent and bead formulation as the Immulite
2500. As true for the Immulite 2500 from Lab A, 3 con-
trols were run with each assay and 2 out of 3 of the
controls must be within 2 standard deviations for the
run to be accepted. The CV’s in Lab C were: I = 5.6,
II = 6.3, and III = 3.6.
Statistics
For each batch of samples, lab, and storage timeframe
(short term, intermediate, and long term), the summary
mean, standard deviation, median, standard errors and
quartile were tabulated. The results were analyzed with
percentage differences to explore the impact of assay
manufacturer and/or time length of frozen storage. Both
mean and median percentage differences were calcu-
lated. Only the mean percentage differences are dis-
played due to the close similarity between the results.
Assay measurement agreement was analyzed in accor-
dance with the Bland Altman method [11,12] by way of
random effects analysis of variance (ANOVA) and by
way of two-way ANOVA. For the two-way ANOVA, the
Welch version of the Student’s test was utilized, because
the group variances were not equal and this method
does not require equal variances in order to obtain valid
tests of statistical inference. Statistical significance was
measured with an alpha = 0.05.
Results
Short term storage - intra-lab
Serum FSH results on the day of the original blood
draw (Lab A only) and after short-term storage of
approximately 45 days (all labs) are shown in Table 1
and are all based on the Short Term Batch samples. The
values range from normal to modestly elevated for a
woman of reproductive age. Comparison within Lab A
between the immediate results and those after 45 days
indicate the impact of short term frozen storage. The
mean degradation was a minimal 4% in this scenario
(Table 2, Comparison 1).
Short term storage - different lab with same assay
manufacturer
Both Lab A and Lab C use an instrument by the same
manufacturer for the FSH assay. Thus, comparison of
Lab A and Lab C results after the identical short term
frozen storage time indicates variability between this
manufacturer’s FSH instruments. In this instance, the
variability is small (5%, Table 2, Comparison 2). Com-
parison of the Lab C results after 45 days of storage to
the Lab A results run on the day of the venipuncture
(Table 2, Comparison 3) shows a 1% difference, thus
reinforcing that that there is little degradation of human
Table 1 Human female serum FSH (IU/L): assay summary
statistics after less than 12 months frozen storage (short
term and intermediate storage times)
Labstorage time Mean (SD) Median (SE) Min, Max Q25, Q75
Lab A0 days 7.31 (3.29) 7.60 (0.85) 2.20, 14.50 5.15, 9.05
Lab A45 days 7.00 (3.02) 7.40 (0.78) 2.10, 12.90 4.70, 8.90
Lab B45 days 6.07 (2.57) 6.47 (0.66) 1.95, 10.53 4.20, 6.72
Lab C 45 days 7.29 (3.01) 7.92 (0.78) 2.18, 12.80 5.00, 9.12
Lab B10.5 months 6.33 (2.79) 6.60 (0.72) 2.10, 11.40 4.55, 7.05
Lab C10.5 months 7.29 (2.96) 7.79 (0.76) 2.31, 12.00 4.95, 9.22
n = 15 samples
SD standard deviation, SE standard error, MIN minimum value, MAX maximum
value, Q25 25
th percentile, Q75 75
th percentile.
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manufacturer variable is held constant. The Bland-Alt-
man limits of agreement are -1.2 mIU/mL to +1.2 mIU/
mL for Lab A and Lab C under this short-term storage
scenario. Figure 1 (bottom right plot) illustrates the
tight standard deviation band; the fact that the band is
centered on zero reinforces the minimal degree of
degradation in this comparison. The degree of variability
in these samples was larger at higher levels of FSH
(p = 0.045, test for trend).
Short term storage - different lab and different assay
manufacturer
T h eF S Hi n s t r u m e n t su s e db yL a b sAa n dBa r ef r o m
different manufacturers. Comparison of the Short Term
Batch results from Lab A and Lab B after the identical
short term frozen storage time indicates variability by
manufacturer in addition to potential differential impact
by storage time. In this instance, the variability is mod-
erate (-12%, Table 2, Comparison 4). Comparison of the
Lab B results after 45 days of storage to the Lab A
r e s u l t so nt h ed a yo fs a m p l ec o l l e c t i o n( T a b l e2 ,C o m -
parison 5) shows -16% degradation, thus implying that
the variability may be due more to differing manufac-
turers than the frozen storage time, as this difference is
similar to Comparison 4. The Bland-Altman limits of
agreement are -3.5 mIU/mL to +1.0 mIU/mL for Lab A
and Lab B under this short-term storage scenario, which
Table 2 Human female serum FSH (IU/L): assay to assay
comparisons after varying length of storage time at -25
degrees C
Comparison Labs and storage
time
Mean Percentage Difference
(SD)
1A 45 days vs. A0 -4% (0.05)
2A 45 days vs. C45 days +5% (0.03)
3A 0 days vs. C45 days +1% (0.07)
4A 45 days vs. B45 days -12% (0.08)
5A 0 days vs. B45 days -16% (0.09)
6B 45 days vs. B10.5 months +4% (0.05)
7C 45 days vs. C10.5 months 0% (0.04)
8A 0 days vs. C2 yrs -23% (0.13)
9A 0 days vs. B2 yrs -25% (0.20)
SD standard deviation
Lab A Assay (mIU/mL)
Assay Measurement Discrepancy
048 1 2 1 6 2 0 2 4
-12
-8
-4
0
4
Lab A Assay (mIU/mL)
Assay Measurement Discrepancy
0 5 10 15 20 25
-12
-8
-4
0
4
Lab A  Assay (mIU/mL)
Assay Measurement Discrepancy
0 5 10 15 20 25
-4
-2
0
2
4
Lab A Assay (mIU/mL)
Assay Measurement Discrepancy
0 5 10 15 20 25
-4
-2
0
2
4
Lab A (0 days) v. Lab B (2 years) Lab A (0 days) v. Lab C (2 years)
Lab A (0 days) v. Lab B (45 days) Lab A (0 days) vs. Lab C (45 days)
Figure 1 Assay measurement agreement by batch and paired labs. For each graph, the difference between the FSH (mIUm/L) values
between two labs is plotted on the y-axis, and the x-axis represents the mean Time 0 Lab A assay value. The degree of agreement is estimated
by calculating the bias, which is represented by the horizontal dashed lines at the mean ± 2 standard deviations. Each graph contains a
comparison between two labs in one batch of samples.
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Lab C. Figure 1 (bottom left plot) illustrates the wider
measurement discrepancy band relative to the “same
manufacturer” comparison above. The degradation in
these samples was greater at higher levels of FSH (p =
0.002, test for trend). The mean percentage degradation
for samples originally less than 10 mIU/mL was 15% vs.
24% for samples ≥ 10 mIU/mL.
Intermediate storage time - intra-lab
Serum FSH results were also evaluated among the Short
Term Batch after intermediate-term storage time by
comparing the 45-day values for Short Term Batch in
Labs B and C vs. the re-run values in Labs B and C
after an additional frozen storage period of nine months
(Table 1 and 2). Within both labs, the mean FSH level
after the additional time in frozen storage was minimal:
+4% in Lab B (Table 2, Comparison 6) and 0% in Lab C
(Table 2, Comparison 7).
Long term storage - different lab and same assay
manufacturer
The impact of long term frozen storage time was evalu-
ated with the Long Term Batch (Table 3). Comparing
the serum FSH level in Lab A on the day of venipunc-
ture with the re-run value from Lab C after 1-3 years of
-25°C storage indicates a significant degradation
occurred in this timeframe (-23%, Table 2, Comparison
8). As these labs use the same assay manufacturer, this
degradation is likely due to the frozen storage time
rather than variability between the labs. The Bland-Alt-
man limits of agreement are -7.2 IU/L to 1.1 IU/L for
Lab A and Lab C under this long-term storage scenario.
T h ed e g r e eo fd e g r a d a t i o ni nthese long-term-storage
samples varied by level of FSH (p = 0.036, test for trend,
Figure 1 top right). Although that test was statistically
significant, the difference in the mean long term percen-
tage degradation by FSH tier was clinically minimal:
25%, 23% and 21% for samples originally ≤ 10 mIU/mL,
10 mIU/mL to 20 mIU/mL, and > 20 mIU/mL,
respectively.
Long term storage - different lab and different assay
manufacturer
FSH levels in Lab B after long-term storage (Long Term
Batch) are shown in Table 3. The mean percentage dif-
ference between the results from Lab A on the day of
the blood draw and the re-run values from Lab B after
1-3 years of frozen storage was -25% (Table 2, Compari-
son 9). The similarity of the degradation in Comparisons
8 and 9 implies that frozen storage time, even at -25°C,
has a greater impact on serum FSH degradation than
variability between assay manufacturers. The Bland-
Altman limits of agreement are -10.1 to 2.5 for Lab A
and Lab B under this long-term storage scenario, mean-
ing that the actual absolute difference between measure-
ments in Lab A and Lab B is between 10.1 IU/L and
-2.5 IU/L. As shown in Figure 1 (top left), the degree of
degradation in these samples was larger at higher levels
of FSH (p < 0.001, test for trend). The mean long term
percentage degradation was 12% for samples originally
≤ 10 mIU/mL vs. 31% for samples between 10 mIU/mL
and 20 mIU/mL vs. 34% for samples > 20 mIU/mL.
Note the wider standard deviation bands in Figure 1 for
both Long Term Batch graphics (top 2 plots) relative to
the Short Term Batch graphics (bottom two plots).
ANOVA calculations - storage time and immunoassay
Two-way ANOVA concluded that the difference in the
storage length (as measured by comparing the two
batches) was statistically significant (p < 0.001), while
the difference in the labs was not statistically significant
(p = 0.066).
Discussion
In summary, these findings indicate that (a) almost all of
the serum FSH measurements after long-term storage at
-25°C are less than the original values with an average
degradation of 25%, and (b) a shorter storage time (less
than 11 months) at -25°C showed much less decline in
immunoreactivity than samples stored for an average of
two years. Also, almost all the serum FSH measure-
ments that used the same assay manufacturer (Labs A
and C) were similar when the frozen storage time was
less than 11 months. Taken together, these results imply
that frozen storage time has a large impact on the
degradation of serum FSH samples, while the specific
immunoassay does not appear to be as important of a
factor in explaining the variation in the FSH values.
This conclusion is supported by the ANOVA results.
The inter-laboratory variation increased directly with
increased frozen storage time at -25°C. This trend was
observed irrespective of which laboratory or immunoas-
say was used. The similarity in the FSH sample mea-
surements after frozen storage times of 4-9 weeks and
10.5 months suggests that serum FSH samples are stable
Table 3 Human female serum FSH (IU/L): assay summary
statistics after long term (median 2 years) storage at -25
degrees C
Labstorage time Mean (SD) Median (SE) Min, Max Q25, Q75
Lab A0 13.33 (5.02) 12.70 (1.30) 5.90, 22.60 9.75, 15.40
Lab B1-3 years 9.53 (3.27) 9.00 (0.84) 5.00, 16.20 7.95, 11.25
Lab C1-3 years 10.27 (4.26) 10.60 (1.10) 3.80, 20.20 7.69, 11.25
n = 15 samples
SD standard deviation, SE standard error, MIN minimum value, MAX maximum
value, Q25 25
th percentile, Q75 75
th percentile.
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the Long Term Batch represent different serum samples,
t h e s ed a t as t r o n g l ys u g g e s tt h a ts e r u mF S Hs a m p l e sd o
degrade to unacceptable levels after 2-3 years of frozen
storage at -25°C. The degree of degradation (-25%
between Labs A and B, -28% between Labs A and C)
after long term frozen storage are unacceptable for
research purposes, with the possible exception of studies
of postmenopausal women where any value > 40 mIU/
mL might be sufficient. The degree of agreement after
short-term storage in the Short Term Batch is markedly
improved (less than 5% variation using the Labs A and
C assay manufacturer).
The results indicate an interesting difference between
assay manufacturers in term of the degradation by FSH
level. These data imply that the long term degradation
is greater at higher levels of FSH with the Abbott Labs
machine (Lab B) more so than with the Immulite
m a c h i n e( L a b sAa n dC ) .T h i si sa na r e af o rf u t u r e
research, as our short term batch had no samples over
15 mIU/mL and neither batch had any samples greater
than 25 mIU/mL.
A strength of this study is the use of three different
laboratories for the assays and two distinct batches of
samples, stored for different lengths of time. The use of
multiple laboratories served to model collaborative
r e s e a r c h .F u r t h e r m o r e ,c o m p a r i n gt w od i f f e r e n tl a b s
that are part of the same institution was helpful for
replicating discrepancies that can occur even within an
institution. Having two different batches of samples fro-
zen for different amounts of time allowed investigation
of the impact of storage time while limiting the freeze-
thaw cycles that could confound the interpretation of
the measurements, unless the original samples were
initially aliquoted into multiple subsamples.
Limitations of this study include a small sample size
and limited population. There were only 30 total sam-
ples in this study, limiting the precision of our conclu-
sions. However, this study can serve as a pilot for
establishing variables for future research on this topic.
The population of samples was limited to women
attending a fertility clinic, some of whom will have
higher than average FSH samples for reproductive age
women. It is possible that the sample degradation may
be different for samples with average FSH values versus
samples with elevated FSH values; the trend test results
imply that possibility. The range of FSH measurements
in the Short Term Batch was narrower than in the Long
Term Batch: the range of Lab A FSH values was 2.2 -
14.5 mIU/mL in the Short Term Batch versus 5.9 - 22.6
mIU/mL in the Long Term Batch. Thus, the samples do
not equally reflect women with elevated, pre-menopau-
sal levels of FSH.
It may also be beneficial in a future study to take the
average of multiple measurements for each sample. In
this study, we only measured each sample once for each
measurement, and this may have allowed for some inac-
curacies because each of these assays has an inherent
variability. In addition, this study had a complex design
with multiple levels of variation in both the length of
frozen storage time and assay manufacturer. Further
studies could be conducted to look at these variables
independently.
This study serves to raise important considerations
when using samples from different sites and the effect
of frozen storage length. Areas for future research
include freezing samples for various lengths of time in
order to determine the degree of degradation as time
progresses in samples stored for longer than 10 months.
Additionally, other temperatures of storage could be
investigated. All these samples were stored at -25°C, but
other storage temperatures may possibly maintain the
sample integrity longer. Urine FSH samples are ideally
stored at 4°C [3], and there is a high correlation
between serum and urine FSH samples, so the tempera-
ture of storage for serum FSH samples needs to be
explored more in order to determine ideal storage
conditions.
In addition, variability may also be related to indivi-
dual laboratory techniques or human lab technique
variability. Each laboratory’s procedure in this study
used a different immunoassay. Therefore, as has been
suggested in previous research on FSH reliability, it may
be useful to have standardized immunoassays within a
research protocol [8].
FSH measurements have important clinical implica-
tions for medical management as well as for entry cri-
teria into studies. Due to the increasing trend towards
having multiple clinical sites collaborate on research stu-
dies in order to increase sample sizes, it is now essential
to ensure that there is acceptable reliability of the FSH
measurement across research labs. This study served to
demonstrate that frozen storage time primarily and
assay manufacturer secondarily may lead to decreased
reliability of the measurements of human serum FSH
samples.
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